Targeting of BRM Sensitizes
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Cell Line, Tumor
Chromatin Assembly and Disassembly
/ drug effects
Chromosomal Proteins, Non-Histone
/ genetics
Combined Modality Therapy
DNA Breaks, Double-Stranded
/ drug effects
DNA Helicases
/ genetics
Epigenesis, Genetic
/ drug effects
Humans
Mutation
/ drug effects
Nuclear Proteins
/ genetics
Rad51 Recombinase
/ genetics
Radiation, Ionizing
Transcription Factors
/ antagonists & inhibitors
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
18
01
2018
revised:
30
06
2018
accepted:
15
11
2018
pubmed:
28
11
2018
medline:
13
3
2020
entrez:
28
11
2018
Statut:
ppublish
Résumé
Targeting of epigenetic regulators as the chromatin remodeler SWI/SNF is proving to be a promising therapeutic strategy for individualized treatment of cancer patients. Here, we tested whether targeting one of the two mutually exclusive subdomains of the SWI/SNF complex BRM/SMARCA2 can sensitize specifically non-small cell lung carcinoma (NSCLC) cells with mutations in the other subunit BRG1/SMARCA4 toward ionizing radiation (IR). Knockdown of BRM with siRNA or shRNA and its consequences for radiation sensitivity as measured by clonogenic survival and plaque-monolayer control was studied in different NSCLC lines with or without
Identifiants
pubmed: 30478150
pii: 1535-7163.MCT-18-0067
doi: 10.1158/1535-7163.MCT-18-0067
doi:
Substances chimiques
Chromosomal Proteins, Non-Histone
0
Nuclear Proteins
0
SMARCA2 protein, human
0
SWI-SNF-B chromatin-remodeling complex
0
Transcription Factors
0
Rad51 Recombinase
EC 2.7.7.-
SMARCA4 protein, human
EC 3.6.1.-
DNA Helicases
EC 3.6.4.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
656-666Informations de copyright
©2018 American Association for Cancer Research.